BRPI0518894A2 - uso da cinase regulada por soro/glicocorticàide - Google Patents
uso da cinase regulada por soro/glicocorticàideInfo
- Publication number
- BRPI0518894A2 BRPI0518894A2 BRPI0518894-6A BRPI0518894A BRPI0518894A2 BR PI0518894 A2 BRPI0518894 A2 BR PI0518894A2 BR PI0518894 A BRPI0518894 A BR PI0518894A BR PI0518894 A2 BRPI0518894 A2 BR PI0518894A2
- Authority
- BR
- Brazil
- Prior art keywords
- regulated kinase
- glucocorticoid
- serum
- fragment
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/105—Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
USO DA CINASE REGULADA POR SOROIG LICOCORTICàIDE. A presente invenção refere-se ao uso de uma proteína de SGK, um derivado funcional ou fragmenta desta, ou um ácido nucléico que codifica uma tal proteína, fragmento ou derivado para descobrir ingredientes ativos para a prevenção ou tratamento de alterações degenerativas da cartilagem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004059781A DE102004059781A1 (de) | 2004-12-10 | 2004-12-10 | Verwendung der Serum-/Glucocorticoid regulierten Kinase |
PCT/EP2005/012802 WO2006061130A2 (de) | 2004-12-10 | 2005-12-01 | Verwendung der serum-/glucocorticoid regulierten kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0518894A2 true BRPI0518894A2 (pt) | 2008-12-16 |
Family
ID=36571126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0518894-6A BRPI0518894A2 (pt) | 2004-12-10 | 2005-12-01 | uso da cinase regulada por soro/glicocorticàide |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080274487A1 (pt) |
EP (1) | EP1825271B1 (pt) |
JP (1) | JP4971991B2 (pt) |
KR (1) | KR101362129B1 (pt) |
CN (1) | CN101073011A (pt) |
AU (1) | AU2005313576B2 (pt) |
BR (1) | BRPI0518894A2 (pt) |
CA (1) | CA2590212A1 (pt) |
DE (1) | DE102004059781A1 (pt) |
IL (2) | IL183466A (pt) |
MX (1) | MX2007006680A (pt) |
WO (1) | WO2006061130A2 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201024733A (en) * | 2008-09-26 | 2010-07-01 | Sanofi Aventis | Methods for determining sodium-proton-exchanger ligand efficiency |
US20130072493A1 (en) | 2011-09-19 | 2013-03-21 | Sanofi | N-[4-(1H-PYRAZOLO[3,4-b]PYRAZIN-6-YL)-PHENYL]-SULFONAMIDES AND THEIR USE AS PHARMACEUTICALS |
PT2570415E (pt) | 2011-09-19 | 2015-11-23 | Sanofi Sa | N-[4-(1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas e a sua utilização como fármacos |
TWI629275B (zh) | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0889127A1 (en) * | 1997-07-01 | 1999-01-07 | Smithkline Beecham Corporation | Serine/threonine protein kinase (H-SGK2) |
WO2001053455A2 (en) * | 1999-12-23 | 2001-07-26 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
DE69937159T2 (de) * | 1998-12-14 | 2008-06-26 | University Of Dundee, Dundee | Verfahren zur Aktivierung von SGK durch Phosphorylierung. |
US6164979A (en) * | 1999-03-12 | 2000-12-26 | Motorola, Inc. | System for providing a removable high density electrical interconnect for flexible circuits |
WO2000073469A2 (en) * | 1999-05-28 | 2000-12-07 | Sugen, Inc. | Protein kinases |
EP1242443A4 (en) * | 1999-12-23 | 2005-06-22 | Nuvelo Inc | NEW NUCLEIC ACIDS AND POLYPEPTIDES |
WO2001055440A1 (en) * | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
US20030092611A9 (en) * | 2000-01-31 | 2003-05-15 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
JP2004504009A (ja) * | 2000-03-06 | 2004-02-12 | スージェン・インコーポレーテッド | 新規ヒト蛋白質キナーゼおよび蛋白質キナーゼ様酵素 |
US20030211989A1 (en) * | 2001-03-02 | 2003-11-13 | Plowman Gregory D | Novel human protein kinases and protein kinase-like enzymes |
US6436703B1 (en) * | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
WO2002024947A2 (en) * | 2000-09-20 | 2002-03-28 | Kinetek Pharmaceuticals, Inc. | Cancer associated protein kinases and their uses |
US7736677B2 (en) * | 2001-06-20 | 2010-06-15 | Metaproteomics, Llc | Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment |
US20030148264A1 (en) * | 2001-07-06 | 2003-08-07 | Genentech, Inc. | Phage displayed PDZ domain ligands |
US6830911B2 (en) * | 2002-02-08 | 2004-12-14 | Applera Corporation | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
WO2003083046A2 (en) * | 2002-03-08 | 2003-10-09 | Curagen Corporation | Novel proteins and nucleic acids encoding same |
WO2003083117A2 (en) * | 2002-04-01 | 2003-10-09 | Asahi Kasei Pharma Corporation | Vascularization controlling gene |
AU2003229689A1 (en) * | 2002-04-15 | 2003-10-27 | Glaxo Group Limited | A method of identifying a modudator for a serine/theronine kinase |
US20040197792A1 (en) | 2002-07-15 | 2004-10-07 | Sugen, Inc. | Novel Kinases |
US20040142864A1 (en) * | 2002-09-16 | 2004-07-22 | Plexxikon, Inc. | Crystal structure of PIM-1 kinase |
EP2322200A3 (en) * | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
AU2003287427A1 (en) * | 2002-11-01 | 2004-06-07 | Incyte Corporation | Kinases and phosphatases |
EP1572118A4 (en) * | 2002-12-20 | 2010-07-14 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216 |
WO2004065577A2 (en) * | 2003-01-14 | 2004-08-05 | Bristol-Myers Squibb Company | Polynucleotides and polypeptides associated with the nf-kb pathway |
DE10305212A1 (de) * | 2003-02-07 | 2004-08-19 | Florian Prof. Dr.med. Lang | Verwendung der sgk-Genfamilie zur Diagnose und zur Therapie von Katarakt und Glaukom |
-
2004
- 2004-12-10 DE DE102004059781A patent/DE102004059781A1/de not_active Withdrawn
-
2005
- 2005-12-01 AU AU2005313576A patent/AU2005313576B2/en not_active Ceased
- 2005-12-01 JP JP2007544776A patent/JP4971991B2/ja not_active Expired - Fee Related
- 2005-12-01 CN CN200580041846.9A patent/CN101073011A/zh active Pending
- 2005-12-01 US US11/720,093 patent/US20080274487A1/en not_active Abandoned
- 2005-12-01 EP EP05817949.0A patent/EP1825271B1/de not_active Not-in-force
- 2005-12-01 CA CA002590212A patent/CA2590212A1/en not_active Abandoned
- 2005-12-01 MX MX2007006680A patent/MX2007006680A/es active IP Right Grant
- 2005-12-01 BR BRPI0518894-6A patent/BRPI0518894A2/pt not_active IP Right Cessation
- 2005-12-01 WO PCT/EP2005/012802 patent/WO2006061130A2/de active Application Filing
- 2005-12-01 KR KR1020077013023A patent/KR101362129B1/ko not_active IP Right Cessation
-
2007
- 2007-05-28 IL IL183466A patent/IL183466A/en not_active IP Right Cessation
-
2011
- 2011-05-12 IL IL212857A patent/IL212857A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2005313576A1 (en) | 2006-06-15 |
WO2006061130A3 (de) | 2007-04-26 |
WO2006061130A2 (de) | 2006-06-15 |
IL183466A0 (en) | 2007-09-20 |
EP1825271B1 (de) | 2014-02-12 |
DE102004059781A1 (de) | 2006-06-22 |
EP1825271A2 (de) | 2007-08-29 |
US20080274487A1 (en) | 2008-11-06 |
AU2005313576B2 (en) | 2011-11-17 |
JP4971991B2 (ja) | 2012-07-11 |
IL212857A0 (en) | 2011-07-31 |
KR101362129B1 (ko) | 2014-02-14 |
CN101073011A (zh) | 2007-11-14 |
CA2590212A1 (en) | 2006-06-15 |
IL183466A (en) | 2013-08-29 |
MX2007006680A (es) | 2007-08-14 |
KR20070085965A (ko) | 2007-08-27 |
JP2008522596A (ja) | 2008-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20071915L (no) | Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer | |
CO6341566A2 (es) | Mutantes fgf21 y usos de de los mismos | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
BRPI0609765A8 (pt) | mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano | |
BRPI0609121B8 (pt) | 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2 | |
BRPI0509172A (pt) | pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento | |
CL2007001388A1 (es) | Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer. | |
BRPI0519690A2 (pt) | composiÇÕes e mÉtodos para modular a expressço de genes usando oligonucleotÍdeos autoprotegidos | |
CO6362020A2 (es) | Mutantes fgf21 y uso de los mismos | |
BR0312464A (pt) | Inibidores de tirosina quinases | |
NO20053972L (no) | Aminosyre-avledede prodrug av propofol, sammensetninger og anvendelse derav. | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
ATE449097T1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer | |
BRPI0610108B8 (pt) | compostos promotores de apoptose e composição que compreende os ditos compostos | |
WO2006124863A3 (en) | Pyrrolopyridine derivatives as protein kinase inhibitors | |
BRPI0611814A2 (pt) | moduladores parp e tratamento de cÂnceres | |
BRPI0507644A (pt) | pirazolopirimidinas como inibidores de cinase dependente de ciclina | |
BRPI0410117A (pt) | composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
BR112012009289A8 (pt) | Método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp) | |
UY28931A1 (es) | Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis | |
BRPI0609278B8 (pt) | método para preparar uma composição farmacêutica e composição farmacêutica | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
BRPI0516533A (pt) | método para o tratamento, inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero que dele necessita; produto; uso de um composto inibidor da tace; composição farmacêutica para o tratamento, a inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero | |
NO20084747L (no) | Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |